Merck MRK, known as MSD outside the United States and Canada, today
said that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT trial has
completed its planned review of study data and recommended that the study
continue.
The study design calls for the collection of 5,250 clinical endpoints. Merck
remains blinded to the actual results of this analysis and to other IMPROVE-IT
safety and efficacy data.
IMPROVE-IT is an 18,141 patient event-driven trial, and based on the targeted
number of clinical endpoints and the rate at which events are being reported,
the trial is projected to conclude in September 2014. The IMPROVE-IT Executive
Committee and Merck will continue to monitor the progress of the study, and
Merck will update the study timeline if appropriate. No additional interim
analyses are planned.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in